Structure-Based Discovery of Quinazolin-2-amine Derivatives as Potent ROR1 Pseudokinase Inhibitors with In Vitro and In Vivo Efficacy against Triple-Negative Breast Cancer
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c01080 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Dehua Lu und 18 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antineoplastic Agents, Protein Kinase Inhibitors, Receptor Tyrosine Kinase-like Orphan Receptors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality, State Key Laboratory of Pharmaceutical Biotechnology.
Abstract (Originalsprache)
As a kind of pseudokinase, although ROR1 lacks the ATP catalytic activity similar to that of classical kinases, it has been proven to play a crucial role in the occurrence and development of triple-negative breast cancer (TNBC). Through structure-based drug design strategy, we have discovered novel quinolin-2-amine ROR1 inhibitor 59 which exhibited excellent binding activity to ROR1 (KD = 0.052 μM) and antiproliferative against breast cancer cells in vitro (IC50 = 0.075 μM) while maintaining good selectivity through kinase profiling screening. Mechanistic studies confirmed 59 could induce cell apoptosis and suppresses ROR1 phosphorylation. In vivo experiments in mice have demonstrated that compound 59 could significantly inhibit the growth (TGI = 92.1% at 20 mg/kg) and metastasis of tumors, moreover 59 showed no significant toxicity. Although the oral bioavailability is relatively low, the overall results confirm that compound 59 can serve as a potential candidate for the treatment of TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
- key Laboratory of Xinjiang Endemic Phytomedicine Resources Ministry of Education; School of Pharmacy, Shihezi University, Shihezi 832003, Xinjiang, China.
ORCID-Profile: Siyu Xiu, Cheng Shi, Song Song, Liangren Zhang, Zhenming Liu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
- State Key Laboratory of Pharmaceutical Biotechnology
Zitieren
APA
Lu, D., Lyu, W., Chi, X., Li, Q., Zhou, Y., Lu, B., Zhang, X., Sun, X., Wang, Z., Xiu, S., Yang, T., Wang, Z., Zheng, R., Zhou, J., Chen, Y., Shi, C., Song, S., Zhang, L., & Liu, Z. (2025). Structure-Based Discovery of Quinazolin-2-amine Derivatives as Potent ROR1 Pseudokinase Inhibitors with In Vitro and In Vivo Efficacy against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01080
Vancouver
Lu D, Lyu W, Chi X, Li Q, Zhou Y, Lu B, et al. Structure-Based Discovery of Quinazolin-2-amine Derivatives as Potent ROR1 Pseudokinase Inhibitors with In Vitro and In Vivo Efficacy against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01080
BibTeX
@article{Lu2025,
author = {Lu, Dehua and Lyu, Weiping and Chi, Xiaowei and Li, Qi and Zhou, Yiran and Lu, Bin and Zhang, Xiangyu and Sun, Xiaojiao and Wang, Zhiqi and Xiu, Siyu and Yang, Tingting and Wang, Zhongwei and Zheng, Ruqiu and Zhou, Jiaxu and Chen, Yanming and Shi, Cheng and Song, Song and Zhang, Liangren and Liu, Zhenming},
title = {Structure-Based Discovery of Quinazolin-2-amine Derivatives as Potent ROR1 Pseudokinase Inhibitors with In Vitro and In Vivo Efficacy against Triple-Negative Breast Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c01080}
}
EUVIMED